We use analytics cookies to understand how readers use the site. They only run if you accept. Privacy policy.
More than 20 FDA-approved targeted therapies and immunotherapy agents now exist for advanced lung cancer. Yet fewer than half of patients in the United States are receiving them. The gap runs almost perfectly along lines of geography, insurance status, and care setting.
Dashed vertical lines mark FDA approval milestones. Modern treatment % = estimated share receiving targeted therapy or immunotherapy. Sources: NCI SEER, FDA.